Bailard, Inc. Ardelyx, Inc. Transaction History

Bailard, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$0.86 - $1.7 $407,046 - $804,627	-473,310 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.27 - $8.17 $300,113 - $1.93 Million	236,310 Added 99.71%	473,310 $625,000
Q2 2021 Aug 13, 2021	SELL	$6.55 - $8.98 $759,800 - $1.04 Million	-116,000 Reduced 32.86%	237,000 $1.8 Million
Q4 2020 Feb 03, 2021	BUY	$5.05 - $7.1 $308,050 - $433,100	61,000 Added 20.89%	353,000 $2.28 Million
Q3 2020 Nov 10, 2020	SELL	$5.25 - $7.08 $914,765 - $1.23 Million	-174,241 Reduced 37.37%	292,000 $1.53 Million
Q2 2020 Aug 12, 2020	SELL	$5.37 - $8.11 $230,373 - $347,919	-42,900 Reduced 8.43%	466,241 $3.23 Million
Q1 2020 Apr 16, 2020	BUY	$4.35 - $8.79 $952,649 - $1.93 Million	219,000 Added 75.48%	509,141 $2.89 Million
Q4 2019 Jan 31, 2020	BUY	$4.23 - $8.29 $1.13 Million - $2.21 Million	267,000 Added 1153.8%	290,141 $2.18 Million
Q1 2019 Apr 24, 2019	BUY	$1.88 - $3.35 $43,505 - $77,522	23,141 New	23,141 $65,000

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $799M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.